

**Brand Name/Active Ingredient:** 'thyroid', 'thyroid', 'thyroid', 'thyroidinum'**Search Date Criteria:** 1965-01-01 to 2014-03-31**Reaction Term(s):** All/Tous**Serious report?:** Both**Type of Report:** All**Source of Report:** All**Gender:** All**Report Outcome:** All**Age:** All

CAVEAT: This summary is based on information from adverse reaction reports submitted by health professionals and laypersons either directly to Health Canada or via market authorization holders. Each report represents the suspicion, opinion or observation of the individual reporter. The Canada Vigilance Program is a spontaneous reporting system that is suitable to detect signals of potential health product safety issues during the post-market period. The data has been collected primarily by a spontaneous surveillance system in which adverse reactions to health products are reported on a voluntary basis. Under reporting of adverse reactions is seen with both voluntary and mandatory spontaneous surveillance systems. Accumulated case reports should not be used as a basis for determining the incidence of a reaction or estimating risk for a particular product as neither the total number of reactions occurring, nor the number of patients exposed to the health product is known. Because of the multiple factors that influence reporting, quantitative comparisons of health product safety cannot be made from the data. Some of these factors include the length of time a drug is marketed, the market share, size and sophistication of the sales force, publicity about an adverse reaction and regulatory actions. In some cases, the reported clinical data is incomplete and there is not certainty that these health products caused the reported reactions. A given reaction may be due to an underlying disease process or to another coincidental factor. This information is provided with the understanding that the data will be appropriately referenced and used in conjunction with this caveat statement.

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000001002	0	1973-10-05	1973-10-05			Spontaneous	Physician

Death:	Disability:	Congenital Anomaly:
Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Male			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DIETAMINE	Suspect	CAPSULE	Oral			2.0 Week(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Congenital hand malformation	v.17.0	
Limb reduction defect	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000001341	0	1973-11-08	1973-11-08	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
40 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
292 FROSST W/PHENACETIN	Concomitant	TABLET	Oral	2.0 Dosage forms	As required	
BENADRYL	Concomitant	NOT SPECIFIED	Oral	25.0 Milligram	4 every 1 Day(s)	
BETNOVATE	Concomitant	NOT SPECIFIED				
DALMANE	Concomitant	CAPSULE	Oral	30.0 Milligram		7.0 Day(s)
DEMEROL	Concomitant	NOT SPECIFIED	Intramuscular	50.0 Milligram	As required	
PROLOID	Suspect	NOT SPECIFIED	Oral	3.0 Grain	1 every 1 Day(s)	9.0 Day(s)
SOLU-CORTEF	Concomitant	POWDER FOR SOLUTION INTRAMUSCULAR		100.0 Milligram	4 every 1 Day(s)	
STEMETIL	Concomitant	NOT SPECIFIED	Intramuscular	10.0 Milligram	4 every 1 Day(s)	
THYROID	Concomitant	NOT SPECIFIED		60.0 Milligram	1 every 1 Day(s)	
VALIUM ORAL	Concomitant	NOT SPECIFIED	Oral	10.0 Milligram	4 every 1 Day(s)	7.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Urticaria	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000001377	0	1973-11-14	1973-11-14			Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
24 Months				Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	TABLET	Oral	3.0 Grain		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Hypothyroidism	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000008601	0	1975-12-24	1975-12-24	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
67 Years	Male		58 Kilograms	Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CORTISONE ACETATE	Concomitant	NOT SPECIFIED	Oral	25.0 Milligram	2 every 1 Day(s)	
HALOTESTIN	Concomitant	TABLET	Oral	5.0 Milligram		
THYROID	Suspect	NOT SPECIFIED	Oral	1.0 Grain	2 every 1 Day(s)	
THYROID	Suspect	NOT SPECIFIED	Oral	2.0 Grain	2 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Diarrhoea	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000013757	0	1977-06-07	1977-06-07	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
86 Years	Male			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CHLORAL HYDRATE SYRUP	Suspect	NOT SPECIFIED	Oral	500.0 Milligram		
MILK OF MAGNESIA	Suspect	NOT SPECIFIED	Oral	30.0 mL	1 every 1 Day(s)	
PHENOBARBITAL	Suspect	NOT SPECIFIED	Oral	15.0 Milligram	4 every 1 Day(s)	
THYROID	Suspect	NOT SPECIFIED	Oral	0.5 Grain	3 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Rash maculo-papular	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime: 2014-07-13 - 09:57:17 AM
Initial Received Date: 1965-01-01 to 2014-03-31
Latest Received Date: N/A
Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000018690	0	1978-10-06	1978-10-06	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
72 Years	Female		41 Kilograms	Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
-------------	-------------------

No duplicate or linked report.

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CALCIUM SANDOZ	Concomitant	NOT SPECIFIED	Oral			
DIGOXIN	Concomitant	NOT SPECIFIED	Oral			
DYAZIDE TAB	Concomitant	TABLET	Oral			
FERGON	Concomitant	NOT SPECIFIED	Oral			2.0 Year(s)
PHENYLBUTAZONE	Concomitant	NOT SPECIFIED	Oral			
PREDNISONE	Concomitant	NOT SPECIFIED	Oral			
THYROID	Suspect	TABLET	Oral	3.0 Grain		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Dyspnoea	v.17.0	
Tachycardia	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000060935	0	1987-09-15	1987-09-15			Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
		Yes	

Patient Information

Age	Gender	Height	Weight	Report Outcome
83 Years	Male	183 Centimetres	83 Kilograms	Not recovered/not resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DIABETA	Concomitant	TABLET	Oral	1.0 Gram		
SYNTHROID	Drug used to treat AE	NOT SPECIFIED	Oral			
THYROID	Suspect	NOT SPECIFIED	Oral	60.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Fatigue	v.17.0	
Hypothyroidism	v.17.0	
Pallor	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000096772	0	1967-10-16	1967-10-16			Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
				Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
222 FROSST W/PHENACETIN	Concomitant	TABLET	Oral	2.0 Dosage forms		
AQUAMOX	Concomitant	TABLET	Oral			
BENDECTIN	Suspect	TABLET	Oral	3.0 Dosage forms		
CALCIUM SANDOZ	Concomitant	NOT SPECIFIED	Oral	10.0 mL		
ENTERO-VIOFORM	Concomitant	NOT SPECIFIED	Oral	4.0 Dosage forms		
EQUANIL TABLETS 400MG	Concomitant	TABLET	Oral			
GELUSIL	Concomitant	NOT SPECIFIED	Oral	1.0 Dosage forms	As required	
IBERET 500	Concomitant	TABLET (EXTENDED-RELEASE)	Oral	1.0 Dosage forms	1 every 1 Day(s)	
PROLOID	Suspect	NOT SPECIFIED	Oral	1.0 Dosage forms	1 every 1 Day(s)	

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
SYM-FER	Concomitant	NOT SPECIFIED	Oral	1.0 Dosage forms	1 every 1 Day(s)	

Adverse Reaction Term Information		
Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Cataract congenital	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000098038	0	1968-06-20	1968-06-20			Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
57 Years	Male	178 Centimetres	80 Kilograms	Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	NOT SPECIFIED	Oral	3.0 Grain		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Myxoedema	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000103491	0	1970-03-24	1970-03-24	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
64 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	NOT SPECIFIED	Oral			60.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Hyperthyroidism	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000104125	0	1970-05-15	1970-05-15			Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
38 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	NOT SPECIFIED	Oral	3.0 Grain		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Lethargy	v.17.0	
Somnolence	v.17.0	
Weight increased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000106122	0	1970-12-29	1970-12-29	Hospital		Spontaneous	

Serious report?		Death:		Disability:		Congenital Anomaly:	
No		Life Threatening:		Hospitalization:		Other Medically Important Conditions:	

Patient Information

Age	Gender	Height	Weight	Report Outcome
2 Years	Female		17 Kilograms	Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	TABLET	Oral	10.0 Dosage forms		1.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Heart rate increased	v.17.0	
Overdose	v.17.0	
Pyrexia	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000106777	0	1971-03-02	1971-03-02	Hospital		Spontaneous	

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
83 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CYCLOSPASMOL TABLETS 200MG	Suspect	TABLET	Oral			16.0 Day(s)
DORIDEN	Suspect	NOT SPECIFIED	Oral			
POLYCILLIN	Suspect	NOT SPECIFIED				16.0 Day(s)
THYROID	Suspect	NOT SPECIFIED	Oral			3.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Urticaria	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000117115	0	1998-03-25	1998-03-25	MAH	JACAN16688	Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
			Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
GAVISCON TABLETS	Suspect	TABLET	Oral		As required	
IMODIUM - CAPLET 2MG	Suspect	TABLET				
LOSEC	Suspect	CAPSULE, DELAYED RELEASE	Oral			1.0 Year(s)
MATERNA	Suspect	TABLET	Oral	1.0 Dosage forms	every 1 Day(s)	
PREPULSID	Suspect	TABLET				24.0 Month(s)
RANITIDINE	Suspect	TABLET	Oral	150.0 Milligram		7.0 Month(s)
THYROID	Suspect	TABLET	Oral			
TYLENOL	Suspect	TABLET	Oral	1000.0 Milligram	As required	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Abortion spontaneous	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000135660	0	2000-11-27	2000-11-27	Community		Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
23 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CONTRACEPTIVES	Concomitant	NOT SPECIFIED	Oral			
T-100 (AOR)	Suspect	TABLET	Unknown	1.0 Dosage forms	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Blood thyroid stimulating hormone decreased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000136477	0	2000-09-27	2000-09-27	MAH	200000176SE	Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
		Yes	

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
ESTROGENS	Concomitant	NOT SPECIFIED	Unknown			
HERBAL PREPARATION	Concomitant	NOT SPECIFIED	Unknown			
MANERIX	Concomitant	TABLET	Unknown			
METHYLPHENIDATE TAB 10MG	Concomitant	NOT SPECIFIED	Unknown			
MINIRIN	Suspect	METERED-DOSE (AEROSOL)	Intra-nasal	5.0 Microgram	every 1 Day(s)	
PROGESTERONE	Concomitant	NOT SPECIFIED	Unknown			
THYROID	Suspect	NOT SPECIFIED	Intra-nasal			

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Dyspnoea	v.17.0	
Hypertension	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000140017	0	2001-06-22	2001-06-22	MAH	0020164M0100002	Spontaneous	Pharmacist

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions: Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	NOT SPECIFIED	Oral	30.0 Milligram	every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Chest discomfort	v.17.0	
Dyspnoea	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000154499	0	2002-09-26	2002-09-26	MAH	2002057825	Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions: Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
66 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
ACETYLSALICYLIC ACID	Concomitant	NOT SPECIFIED	Oral			
THYROID	Suspect	NOT SPECIFIED	Oral	150.0 Milligram	every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Anger	v.17.0	
Cerebrovascular accident	v.17.0	
Therapeutic response decreased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000160320	0	2003-04-17	2003-04-17			Spontaneous	Pharmacist

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
46 Years	Female	157 Centimetres	59 Kilograms	Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
-------------	-------------------

No duplicate or linked report.

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
ATROVENT	Concomitant	NOT SPECIFIED				
FLONASE - AEM-SUS NAS 50MCG/MD	Concomitant	METERED-DOSE (PUMP)	Inhalation			
FLOVENT	Concomitant	NOT SPECIFIED				
SALBUTAMOL	Concomitant	NOT SPECIFIED	Inhalation			
THYROID	Suspect	NOT SPECIFIED	Oral	30.0 Milligram	1 every 1 Day(s)	7.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Pruritus genital	v.17.0	
Vulvovaginal discomfort	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000173055	0	2004-07-28	2004-07-28	MAH	2004048026	Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
			Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Not recovered/not resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CORTICOSTEROID(S)	Drug used to treat AE	NOT SPECIFIED	Unknown			
THYROID (PFIZER)	Suspect	TABLET	Oral	125.0 Milligram	every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Adrenal insufficiency	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000346446	1	2010-06-28	2010-07-20	MAH	RNC10001	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
44 Years	Male			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	1 every 1 Day(s)	1.0 Month(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Acne	v.17.0	
Dizziness	v.17.0	
Product quality issue	v.17.0	
Product taste abnormal	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000347656	0	2010-07-20	2010-07-20	MAH	RNC10009	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
30 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	3 every 1 Day(s)	3.0 Week(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Feeling abnormal	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000347657	0	2010-07-20	2010-07-20	MAH	RNC10010	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
52 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	1 every 1 Day(s)	3.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Alopecia	v.17.0	
Asthenia	v.17.0	
Onychoclasia	v.17.0	
Psoriasis	v.17.0	
Rash	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000347658	0	2010-07-20	2010-07-20	MAH	RNC10014	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
53 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	2.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Pain in extremity	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000358486	0	2010-12-23	2010-12-23	MAH	RNC10034	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
35 Years	Female	174 Centimetres	58 Kilograms	Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	1 every 1 Day(s)	167.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Alopecia	v.17.0	
Vitamin B12 decreased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000358519	0	2010-12-23	2010-12-23	MAH	RNC010022	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
85 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Disorientation	v.17.0	
Malaise	v.17.0	
Neck pain	v.17.0	
Pain	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000358558	0	2010-12-23	2010-12-23	MAH	RNC10036	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
62 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	2.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Drug ineffective	v.17.0	
Fatigue	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000366215	0	2011-04-12	2011-04-12	Community		Spontaneous	Pharmacist

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DESICCATED THYROID (PORCINE)	Suspect	NOT SPECIFIED	Oral	60.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Heart rate increased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000369331	0	2011-05-24	2011-05-24	Community		Spontaneous	Pharmacist

Serious report?		Death:		Disability:		Congenital Anomaly:	
No		Life Threatening:		Hospitalization:		Other Medically Important Conditions:	

Patient Information

Age	Gender	Height	Weight	Report Outcome
53 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DESICCATED THYROID (PORCINE)	Suspect	NOT SPECIFIED	Oral	60.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Blood pressure decreased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000378432	0	2011-09-08	2011-09-08	MAH	RNC11014	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
56 Years	Male			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DIOVAN	Concomitant	NOT SPECIFIED	Unknown			
LAMICTAL	Concomitant	TABLET	Unknown			
THYROID TAB 125MG	Suspect	TABLET	Oral	125.0 Milligram	1 every 1 Day(s)	366.0 Day(s)
THYROID TAB 30MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	366.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Condition aggravated	v.17.0	
Depression	v.17.0	
Fatigue	v.17.0	
Feeling abnormal	v.17.0	
Tri-iodothyronine decreased	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000380676	0	2011-10-03	2011-10-03	MAH	RNC11019	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
64 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	32.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Blood pressure increased	v.17.0	
Fatigue	v.17.0	
Rash	v.17.0	
Vaginal discharge	v.17.0	
Weight increased	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000380719	0	2011-10-04	2011-10-04	MAH	RNC11018	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
57 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	32.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Oropharyngeal pain	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000393727	0	2011-12-08	2011-12-08	MAH	RNC11020	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
32 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	TABLET	Oral	30.0 Milligram	2 every 1 Day(s)	1.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Dizziness	v.17.0	
Fatigue	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000400418	0	2012-01-05	2012-01-05	MAH	RNC11021	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	2 every 1 Day(s)	2.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
General physical health deterioration	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000400419	0	2012-01-05	2012-01-05	MAH	RNC11030	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral			

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Drug ineffective	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000400425	0	2012-01-05	2012-01-05	MAH	RNC11031	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
50 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Drug ineffective	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000404531	0	2012-01-23	2012-01-23	MAH	RNC12001	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
42 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
COENZYME Q10	Concomitant	NOT SPECIFIED				
GRAPE SEED EXTRACT	Concomitant	NOT SPECIFIED				
OMEGA	Concomitant	NOT SPECIFIED				
OMEGA - 3	Concomitant	NOT SPECIFIED				
PRIMROSE OIL	Concomitant	NOT SPECIFIED				
THYROID TAB 30MG	Suspect	TABLET	Oral	75.0 Milligram	1 every 1 Day(s)	3.5 Year(s)
VITAMIN C	Concomitant	NOT SPECIFIED				
VITAMIN D	Concomitant	NOT SPECIFIED				

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Eye swelling	v.17.0	
Urticaria	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000405563	0	2012-01-25	2012-01-25	MAH	RNC12002	Spontaneous	Consumer Or Other Non Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
56 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	1.5 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Hot flush	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000413164	0	2012-02-09	2012-02-09	MAH	RNC12006	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
55 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Oral	45.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Drug ineffective	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000413169	0	2012-02-21	2012-02-21	MAH	RNC12005	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
63 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	7.0 Year(s)
THYROID	Suspect		Oral	3.0 Dosage forms		
THYROID TAB 125MG	Suspect	TABLET	Oral	125.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Body temperature decreased	v.17.0	
Fatigue	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000423726	0	2012-03-26	2012-03-26	MAH	RNC12008	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
79 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
MULTIVITAMINE(S)	Concomitant	NOT SPECIFIED				
THYROID TAB 30MG	Suspect	TABLET	Oral	45.0 Milligram	1 every 2 Day(s)	43.0 Year(s)
THYROID TAB 30MG	Suspect		Oral	60.0 Milligram	1 every 2 Day(s)	43.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Nervousness	v.17.0	
Palpitations	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000431058	0	2012-04-24	2012-04-24	MAH	RNC12011	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
46 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
KEPPRA	Concomitant	TABLET				
THYROID	Suspect	TABLET	Oral	30.0 Milligram	2 every 1 Day(s)	3.0 Day(s)
VIMPAT	Concomitant	NOT SPECIFIED				

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Cough	v.17.0	
Dyspnoea	v.17.0	
Gingival swelling	v.17.0	
Lacrimation increased	v.17.0	
Sneezing	v.17.0	
Temperature regulation disorder	v.17.0	
Tongue disorder	v.17.0	

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Urticaria	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000447831	0	2012-06-30	2012-06-30	Hospital		Spontaneous	Pharmacist

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
			Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
24 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
EPINEPHRINE	Concomitant	NOT SPECIFIED				
HGH+ HOMEOPATHIC	Suspect	LIQUID SUBLINGUAL	Sublingual	8.0 Drops		

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Hypertension	v.17.0	
Mydriasis	v.17.0	
Tachycardia	v.17.0	
Tremor	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000451755	0	2012-07-19	2012-07-19	MAH	RNC12023	Spontaneous	Other Health Professional

Serious report? Yes	Death:	Disability: Yes	Congenital Anomaly:
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
50 Years	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
DESICCATED THYROID (PORCINE)	Suspect	NOT SPECIFIED	Oral	120.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Rash maculo-papular	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000485886	0	2012-11-29	2012-11-29	MAH	RNC12031	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
69 Years	Female			Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID (PFIZER)	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	1.0 Month(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Chest pain	v.17.0	
Condition aggravated	v.17.0	
Dizziness	v.17.0	
Dyspnoea	v.17.0	
Oedema peripheral	v.17.0	
Tinnitus	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000488819	0	2012-12-13	2012-12-13	MAH	RNC12033	Spontaneous	Physician

Serious report? Yes	Death:	Disability: Yes	Congenital Anomaly:
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female	164 Centimetres	50 Kilograms	Recovering/resolving

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 30MG	Suspect	TABLET	Unknown	30.0 Milligram	2 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Back pain	v.17.0	
Nasopharyngitis	v.17.0	
Pain in extremity	v.17.0	
Somnolence	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000526656	0	2013-05-15	2013-05-15	MAH	RNC13010	Spontaneous	Physician

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions: Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
55 Years	Female	167 Centimetres	72 Kilograms	Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
ADRENAL SUPPLEMENT	Concomitant					
MULTIVITAMINE(S)	Concomitant	NOT SPECIFIED				
OMEGA - 3	Concomitant	NOT SPECIFIED				
THYROID TAB 30MG	Suspect	TABLET	Unknown	30.0 Milligram	1 every 1 Day(s)	4.0 Year(s)
VITAMIN D	Concomitant	NOT SPECIFIED				

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Anger	v.17.0	
Hypersensitivity	v.17.0	
Skin burning sensation	v.17.0	
Throat irritation	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000530380	0	2013-05-30	2013-05-30	MAH	RNC13013	Spontaneous	Physician

Serious report? Yes	Death:	Disability: Yes	Congenital Anomaly:
	Life Threatening:	Hospitalization:	Other Medically Important Conditions: Yes

Patient Information

Age	Gender	Height	Weight	Report Outcome
43 Years	Male	178 Centimetres	130 Kilograms	Unknown

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
CETIRIZINE	Concomitant	TABLET				
THYROID TAB 60MG	Suspect	TABLET	Oral	60.0 Milligram	1 every 1 Day(s)	50.0 Day(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Abdominal distension	v.17.0	
Alopecia	v.17.0	
Pain in extremity	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000539693	0	2013-07-08	2013-07-08	MAH	RNC13019	Spontaneous	Physician

Serious report? Yes	Death:	Disability:	Congenital Anomaly:
	Life Threatening: Yes	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
61 Years	Male		100 Kilograms	Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
SYNTHROID	Suspect	NOT SPECIFIED	Oral	100.0 Microcurie s	1 every 1 Day(s)	
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	1 every 1 Day(s)	

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Blood pressure systolic increased	v.17.0	
Blood thyroid stimulating hormone increased	v.17.0	
Fatigue	v.17.0	
Somnolence	v.17.0	
Thyroxine decreased	v.17.0	
Tri-iodothyronine increased	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000541388	0	2013-07-15	2013-07-15	MAH	RNC-13-020	Spontaneous	Physician

Serious report? Yes	Death:	Disability: Yes	Congenital Anomaly:
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
40 Years	Male	187 Centimetres	102 Kilograms	Recovering/resolving

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 60MG	Suspect	TABLET	Oral	90.0 Milligram	1 every 1 Day(s)	1.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Fatigue	v.17.0	
Feeling abnormal	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000569389	0	2013-11-07	2013-11-07	MAH	RNC-13-029	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
Yes			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:
		Yes	

Patient Information

Age	Gender	Height	Weight	Report Outcome
	Female			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 125MG	Suspect	TABLET	Unknown			
THYROID TAB 30MG	Suspect	TABLET	Unknown			
THYROID TAB 60MG	Suspect	TABLET	Unknown			

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Asthenia	v.17.0	
Fatigue	v.17.0	
Hyperthyroidism	v.17.0	
Weight increased	v.17.0	

**Canada Vigilance
Summary of Reported Adverse Reactions**

Report Runtime: 2014-07-13 - 09:57:17 AM
 Initial Received Date: 1965-01-01 to 2014-03-31
 Latest Received Date: N/A
 Total Number of Reports: 53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000574343	0	2013-11-28	2013-11-28	MAH	RNC-13-035	Spontaneous	Other Health Professional

Serious report?	Death:	Disability: Yes	Congenital Anomaly:
Yes	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
69 Years	Male			Recovered/resolved

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
THYROID TAB 125MG	Suspect	TABLET	Unknown			
THYROID TAB 30MG	Suspect	TABLET	Unknown	60.0 Milligram	1 every 1 Day(s)	
THYROID TAB 60MG	Suspect	TABLET	Unknown			

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Back pain	v.17.0	
Fatigue	v.17.0	
Joint stiffness	v.17.0	

Canada Vigilance Summary of Reported Adverse Reactions

Report Runtime:	2014-07-13 - 09:57:17 AM
Initial Received Date:	1965-01-01 to 2014-03-31
Latest Received Date:	N/A
Total Number of Reports:	53 Report(s)

Report Information

**AER = Adverse Reaction Report

Adverse Reaction Report Number	Latest AER Version Number	Initial Received Date	Latest Received Date	Source of Report	Market Authorization Holder AER Number	Type of Report	Reporter Type
000596062	0	2014-02-27	2014-02-27	MAH	RNC-	Spontaneous	Other Health Professional

Serious report?	Death:	Disability:	Congenital Anomaly:
No			
	Life Threatening:	Hospitalization:	Other Medically Important Conditions:

Patient Information

Age	Gender	Height	Weight	Report Outcome
72 Years	Female			Recovering/resolving

Link / Duplicate Report Information

Record Type	Link AER** Number
No duplicate or linked report.	

Product Information

Product Description	Health Product Role	Dosage Form	Route of Administration	Dose	Frequency	Therapy Duration
MULTIVITAMINE(S)	Concomitant	NOT SPECIFIED				
THYROID TAB 30MG	Suspect	TABLET	Oral	30.0 Milligram	3 every 1 Day(s)	4.0 Year(s)

Adverse Reaction Term Information

Adverse Reaction Term(s)	MedDRA Version	Reaction Duration
Nausea	v.17.0	
Product quality issue	v.17.0	
Vertigo	v.17.0	